Cancer Chemoprevention Research Interest Group Bios

Where You Are:

Nagi Kumar, PhD, RD, FADA, Senior Member, Director, Cancer Chemoprevention

Dr. Kumar focuses her research on examining the role of botanicals, biologics and other agents for cancer chemoprevention and to ameliorate symptoms of cancer treatment. Using a systematic, science-based approach, and working with a multidisciplinary team, Dr. Kumar has initiated and completed several preclinical and early phase I-II clinical trials with purified isoflavones, curcuminoid complex, green tea catechins, n-3 fatty acids, tannic acid and lycopene, laying the foundation to develop a program to accelerate agent development and validation at Moffitt Cancer Center. Funded by the National Institute of Health, the Program currently has two active phase II clinical trials evaluating the safety and effectiveness of polyphenon E and in preventing progression of prostate cancer. Dr. Kumar is also the Moffitt PI of a study funded by Novartis pharma to evaluate the safety and effectiveness of a novel agent BYM338X2202 in preventing progression of cancer cachexia. Additionally, a grant was received from Indo-US S&T Forum (IUSSTF) to conduct an Indo-US Bilateral Workshop on Accelerating Botanicals and Biologics Agent Development Research for Cancer Chemoprevention, Treatment and Survival. This year, Dr. Kumar received funding from Gateway foundation to evaluate the safety and effectiveness of a combination therapy with blueberry anthocyanins and omega-3 fatty acids (COGNUTRIN) in ameliorating chemotherapy-induced cognitive impairment in breast cancer patients receiving adjuvant chemotherapy.

  • Chornokur G, Kumar NB. Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research. Cancer Causes Control. 2013 Jun. Pubmedid: 23737026.
  • Deng GE, Rausch SM, Jones LW, Gulati A, Kumar NB, Greenlee H, Pietanza MC, Cassileth BR. Complementary Therapies and Integrative Medicine in Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013 May;143(5 Suppl):e420S-e436S. Pubmedid: 23649450.
  • Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. 2012 Sep;21(5):407-412. Pubmedid: 22156994. Pmcid: PMC3319490.
  • Connors SK, Chornokur G, Kumar NB. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer. 2012 Jul;64(1):4-22. Pubmedid: 22098273. Pmcid: PMC3665011.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Jun;33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.
  • Ribeiro MdLC, Silva AS, Bailey KM, Kumar NB, Sellers TA, Gatenby RA, Arig IH, Gillies RJ. Buffer therapy for cancer. J Nutr Food Sci. 2012 Jan;1-7.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Connors S, Chornukur G, Dickinson SI, Bai W, Williams CR, Salup R, Fu W. Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. J Cancer Sci Ther. 2012 Jan;2011(S3). Pubmedid: 22422102.
  • Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate. 2011 Jul;71(9):985-997. Pubmedid: 21541975. Pmcid: PMC3083484.
  • Brem S, Kumar NB. Management of treatment-related symptoms in patients with breast cancer. Clin J Oncol Nurs. 2011 Feb;15(1):63-71. Pubmedid: 21278042.
  • Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, Reddy K, Hastings S, Exterman M, Balducci L, Dalton K, Bepler G. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol. 2010 Dec;11(3-4):107-117. Pubmedid: 21128029. Pmcid: PMC3016925.
  • Kumar NB, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Besterman-Dahan K, Krischer JP. Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol. 2010 Winter;8(1):3-13. Pubmedid: 20205984.
  • Kumar N, Titus-Ernstoff L, Newcomb PA, Trentham-Dietz A, Anic G, Egan KM. Tea consumption and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):341-345. Pubmedid: 19124518. Pmcid: PMC3156033.
  • Sellers TA, Vierkant RA, Djeu J, Celis E, Wang AH, Kumar N, Cerhan JR. Unpasteurized milk consumption and subsequent risk of cancer. Cancer Causes Control. 2008 Oct;19(8):805-811. Pubmedid: 18344007.
  • Dahan K, Fennal M, Kumar NB. Lycopene in the prevention of prostate cancer. J Soc Integr Oncol. 2008;6(1):29-36. Pubmedid: 18302908.
  • Cassileth BR, Deng GE, Gomez JE, Johnstone PA, Kumar N, Vickers AJ. Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):340S-354S. Pubmedid: 17873179.
  • Kumar N, Shibata D, Helm J, Coppola D, Malafa M. Green tea polyphenols in the prevention of colon cancer. Front Biosci. 2007;12:2309-2315. Pubmedid: 17127241.
  • Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J. A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer. 2007;59(2):163-168. Pubmedid: 18001210. Pmcid: PMC2435485.
  • Kumar N, Allen K, Bell H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control. 2005 Jul;12(3):149-157. Pubmedid: 16062162.
  • Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev. 2004 May;62(5):204-211. Pubmedid: 15212320.
  • Kumar N, Allen K, Riccardi D, Kazi A, Heine J. Isoflavones in breast cancer chemoprevention: where do we go from here. Front Biosci. 2004;9:2927-2934. Pubmedid: 15353326.
  • Kazi A, Wang Z, Kumar N, Falsetti S, Chan T, Dou Q. Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors. Anticancer Res. 2004;24(2B):943-954. Pubmedid: 15161048.
  • Kumar N, Dalton K. Eicosapentaenoic acid: promising nutritional supplement in the treatment of cancer cachexia in elderly patients. J Evidence-Based Integrative Medicine. 2004;1(3):189-194. Pubmedid: noPMID.
  • Kumar N, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004;59(2):141-147. Pubmedid: 15042614.
  • Kazi A, Daniel KG, Smith DM, Kumar NB, Dou QP. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol. 2003 Sep;66(6):965-976. Pubmedid: 12963483.
  • Kazi A, Urbizu D, Kuhn D, Acebo A, Jackson E, Greenfelder G, Kumar N, Dou Q. A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells. Int J Mol Med. 2003;12(6):879-887. Pubmedid: 14612961.
  • Kumar NB, Cantor A, Allen K, Riccardi D, Cox CE. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer. 2002 Feb;94(4):1166-1174. Pubmedid: 11920488. Pmcid: PMC2377415.
  • Kumar N, Besterman-Dahan K. Nutrients in the chemoprevention of prostate cancer: current and future prospects. Cancer Control. 1999;6(6):580-586. Pubmedid: 10756389.

Mokenge P. Malafa, MD, Senior Member, Chair/Program Leader, GI Oncology

Dr. Malafa's research group focuses on vitamin E signaling pathways and biomarkers in pancreatic cancer. Previously his group demonstrated vitamin E succinate inhibition of oncogenic Ras signaling pathways (Donapaty et al, Molecular Cancer Therapeutics, 2006). Following up on this work, his group identified the most bioactive vitamin E analogue, delta-tocotrienol, in pancreatic cancer cells and reported that therapeutic levels of delta-tocotrienol was achieved in mice pancreas following oral administration. Dr. Malafa and his collaborators have embarked on a strategy to comprehend signaling pathways active in pancreatic cancer cells and targeted by vitamin E delta-tocotrienol, employing affinity chromatography, chemical proteomics, and mass spectrometry to identify direct interacting proteins. They identified nearly 20 different protein targets of delta-tocotrienol. One of the targets, hCAS, was shown to be is a relevant target of delta-tocotrienol action and a valid novel target in pancreatic and colorectal cancers. Future directions in the lab consist of using small molecule-protein binding interactions to define the biochemical target(s) of vitamin E tocotrienol anticancer activity and thereby identify novel targets for the prevention of malignancy
  • Hodul PJ, Dong Y, Husain K, Pimiento JM, Chen J, Zhang A, Francois R, Pledger WJ, Coppola D, Sebti SM, Chen DT, Malafa MP. Vitamin E δ-Tocotrienol Induces p27(Kip1)-Dependent Cell-Cycle Arrest in Pancreatic Cancer Cells via an E2F-1-Dependent Mechanism. PLoS One. 2013;8(2):e52526. Pubmedid: 23393547.
  • Husain K, Francois RA, Yamauchi T, Perez M, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer. Mol Cancer Ther. 2012 May;10(12):2363-2372. Pubmedid: 21971120. Pmcid: PMC3237822.
  • Husain K, Francois RA, Hutchinson SZ, Neuger AM, Lush R, Coppola D, Sebti S, Malafa MP. Vitamin E delta-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration. Pharmacology. 2009;83(3):157-163. Pubmedid: 19142032. Pmcid: PMC2834260.
  • Kumar N, Shibata D, Helm J, Coppola D, Malafa M. Green tea polyphenols in the prevention of colon cancer. Front Biosci. 2007;12:2309-2315. Pubmedid: 17127241.
  • Malafa M, Fokum F, Andoh J, Neitzel L, Bandyopadhyay S, Zhan R, IiizumiM, Furuta E, Horvath E, Watabe K. Vitamin E succinate suppresses prostate tumor growth by inducing apoptosis. Int J Cancer. 2006 May;118(10):2441-2447. Pubmedid: 16380976.
  • Donapaty S, Louis S, Horvath E, Kun J, Sebti SM, Malafa MP. RRR-alpha-tocopherol succinate down-regulates oncogenic Ras signaling. Mol Cancer Ther. 2006 Feb;5(2):309-316. Pubmedid: 16505104.
  • Malafa MP, Fokum FD, Smith L, Louis A. Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate. Ann Surg Oncol. 2002 Dec;9(10):1023-1032. Pubmedid: 12464597.
  • Malafa M, Fokum F, Mowlavi A, Abusief M, King M. Vitamin E inhibits melanoma growth in mice. Surgery. 2002;131(1):85-91. Pubmedid: 11812968.
  • Barnett K, Fokum F, Malafa M. Vitamin E succinate inhibits colon cancer liver metastases. J Surg Res. 2002;106(2):292-298. Pubmedid: 12175981.
  • Husain K, Centeno BA, Chen DT, Fulp WJ, Perez M, Zhang Lee G, Luetteke N, Hingorani SR, Sebti SM, Malafa MP. Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol. Carcinogenesis. 2013 Jun;34(4):858-863. Pubmedid: 23302291. Pmcid: PMC3616675.

Patricia Judson, MD, Associate Member, Women’s Oncology

Dr. Judson performs clinical research in all areas of gynecologic oncology and serves on the Gynecologic Oncology Group’s (GOG) Quality of Life Committee. Additionally she is conducting research evaluating complementary and alternative therapies and their effects on women and cancer outcomes.

  • Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Zgheib NB, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM. Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer. 2012 Jul;22(6):960-967. Pubmedid: 22740002.
  • Judson PL, Dickson EL, Argenta PA, Xiong Y, Geller MA, Carson LF, Ghebre R, Jonson AL, Downs LS. A prospective, randomized trial of integrative medicine for women with ovarian cancer. Gynecol Oncol. 2011 Dec;123(2):346-350. Pubmedid: 21864886. Pmcid: PMC3393038.

Julie Djeu, PhD, Senior Member, Associate Center Director, Cancer Education

Dr. Julie Djeu, Ph.D., is a Senior Member, Associate Center Director, Cancer Education and training, Scientific Director, Flow Cytometry Core Facility, Manuel and Adeline Garcia Center Director's Chair for Leadership. She is a tumor immunologist, with expertise in cytokines and immune regulation, beginning from discovery of NK cells and cytokine biology to analysis of tumor-induced T cell immune modulation involving IL10 and IL12. Dr. Djeu’s interest included identification and evaluation of the safety and effectiveness of novel agents that can modulate inflammatory pathways to prevent cancer as well as ameliorate symptoms of cancer and cancer treatment.

  • Zhou J, Wu J, Chen X, Fortenbery N, Eksioglu E, Kodumudi KN, Epling-Burnette PK, Dong J, Djeu JY, Wei S. Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. Int Immunopharmacol. 2011 Oct;11(7):890-898. Pubmedid: 21244860. Pmcid: PMC3109231.
  • Sellers TA, Vierkant RA, Djeu J, Celis E, Wang AH, Kumar N, Cerhan JR. Unpasteurized milk consumption and subsequent risk of cancer. Cancer Causes Control. 2008 Oct;19(8):805-811. Pubmedid: 18344007.

Jhanelle Gray, MD, Assistant Member, Thoracic Oncology

Dr. Gray’s research focuses on the analysis of targeted therapies in patients with non-small lung cancer (NSCLC) and those at risk for lung cancer with hopes of optimizing the therapeutic benefit while minimizing the toxicity with the use of biomarker analysis to enhance the understanding of cancer biology and treatment.She was the principal investigator of a phase IIB randomized, placebo-controlled, double-blind study of enzastaurin (a protein kinase C inhibitor), investigating its efficacy in lung cancer prevention in former smokers. Through her continued work on this project, she was awarded an NIH Specialized Program of Research Excellence (SPORE) supplement grant (Research Supplements to Promote Diversity in Health-Related Research). Additionally Dr. Gray is involved in analyzing histone deacetylase (HDAC) inhibitors as a novel treatment approach in patients with lung cancer. One strategy to enhance the efficacy of the EGFR tyrosine kinase inhibitor, already demonstrated in vitro, is to combine erlotinib with inhibitors of other key oncogenic pathways such as HDAC inhibitors. Dr. Gray and colleagues also are exploring additional HDAC inhibitor combination strategies for clinical application.

  • Gray JE, Altiok S, Alexandrow MG, Walsh FW, Chen J, Schell MJ, Tai DF, Bepler G. Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers. Cancer. 2013 Mar;119(5):1023-1032. Pubmedid: 23065656. Pmcid: PMC3578040.
  • Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. 2012 Sep;21(5):407-412. Pubmedid: 22156994. Pmcid: PMC3319490.
  • Gray J, Mao J, Szabo E, Kelley M, Kurie J, Bepler G. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest. 2007 Sep;132(3 Suppl):56S-68S. Pubmedid: 17873160.
  • Gray J, Alberts W, Bepler G. Statins and lung cancer risk. Chest. 2007 May;131(5):1274-1275. Pubmedid: 17494775.
 
 
 
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions